- Correction
- Open access
- Published:
Correction: Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway
Journal of Experimental & Clinical Cancer Research volume 42, Article number: 241 (2023)
The Original Article was published on 12 October 2018
Correction: J Exp Clin Cancer Res 37, 248 (2018)
Following publication of the original article [1], errors were found in Figs. 6 and 8. The band of β-actin in Fig. 6B (Basal) and the band of CD31 in Fig. 8F were mistakenly uploaded.
The corrected figures are provided below:
Effect of Andro on VEGF-induced angiogenesis. a HUVECs were exposed to Andro at the indicated doses, and viability was measured by CCK-8 assay. Data were represented as percentage of vehicle-treated control. b The expression level of COX-2 protein was analyzed by Western blot HUVECs treated with the indicated doses of Andro for 48 h, with or without VEGF induction. c-d Effects of Andro on tube formation on Matrigel c at 6 h (Original magnifcation, 50 ×), and sprouting from modifed human endothelial cell spheroids d at 24 h (Original magnifcation, 200 ×). Experiments were performed with or without VEGF and indicated Andro doses. (##p < 0.01, VEGF-treated group vs. Solvent; *P < 0.05, **P < 0.01, Andro treatment vs vehicle control groups)
Effect of Andro on tumor growth and tumor angiogenesis in a breast cancer mouse model. An orthotopic mouse model of human breast cancer MDA-MB-231 cells was used to evaluate the anti-tumor effect of Andro. The tumor pictures (a), tumor volumes (b) and total weights (c) were measured. d The expressions of COX-2 and CD31 in tumor samples were analyzed by immunohistochemistry and cofocol immunofluorescence, respectively. e The quantitative analysis of relative COX-2 expression and microvessel number were also performed. f The expression of COX-2 and CD31 proteins in tumor tissues was analyzed by Western blot. Data were represented as the mean ± S.D. (*P < 0.05, **P < 0.01, Andro treatment vs vehicle control groups, N = 5 mice/group. Magnification, 200 ×)
The corrections do not affect the overall result, discussion, or conclusion of the article.
Reference
Peng Y, Wang Y, Tang N, et al. Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway. J Exp Clin Cancer Res. 2018;37:248. https://doi.org/10.1186/s13046-018-0926-9.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Peng, Y., Wang, Y., Tang, N. et al. Correction: Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway. J Exp Clin Cancer Res 42, 241 (2023). https://doi.org/10.1186/s13046-023-02818-7
Published:
DOI: https://doi.org/10.1186/s13046-023-02818-7